keyword
MENU ▼
Read by QxMD icon Read
search

Uterine carcinosarcoma

keyword
https://www.readbyqxmd.com/read/28630682/overexpressed-prame-is-a-potential-immunotherapy-target-in-sarcoma-subtypes
#1
Jason Roszik, Wei-Lien Wang, John A Livingston, Christina L Roland, Vinod Ravi, Cassian Yee, Patrick Hwu, Andrew Futreal, Alexander J Lazar, Shreyaskumar R Patel, Anthony P Conley
BACKGROUND: PRAME (preferentially expressed antigen in melanoma), a member of the cancer-testis antigen family, has been shown to have increased expression in solid tumors, including sarcoma, and PRAME-specific therapies are currently in development for other cancers such as melanoma. METHODS: To map the landscape of PRAME expression in sarcoma, we used publicly available data from The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE) projects and determined which sarcoma subtypes and subsets are associated with increased PRAME expression...
2017: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/28625393/establishment-and-characterization-of-uterine-sarcoma-and-carcinosarcoma-patient-derived-xenograft-models
#2
Tine Cuppens, Jeroen Depreeuw, Daniela Annibali, Debby Thomas, Els Hermans, Ellen Gommé, Xuan Bich Trinh, David Debruyne, Philippe Moerman, Diether Lambrechts, Frédéric Amant
OBJECTIVE: Uterine sarcomas (US) and carcinosarcomas (CS) are rare, aggressive cancers. The lack of reliable preclinical models hampers the search for new treatment strategies and predictive biomarkers. To this end, we established and characterized US and CS patient-derived xenograft (PDX) models. METHODS: Tumor fragments of US and CS were subcutaneously implanted into immunocompromised mice. Engrafted xenograft and original tumors were compared by means of histology, immunohistochemistry, whole-genome low-coverage sequencing for copy number variations, and RNA sequencing...
June 16, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28625283/uterine-and-ovarian-carcinosarcomas-do-they-behave-similarly
#3
Isin Ureyen, Alper Karalok, Derya Akdag Cirik, Tolga Tasci, Zeynep Kestel Gokce, Ipeknur Balin Duzguner, Gokhan Tulunay, Taner Turan
OBJECTIVE: We aimed to compare the clinicopathologic characteristics, recurrence patterns, and survival of patients with ovarian carcinosarcomas (OCs) and uterine carcinosarcomas (UCs). METHODS: Patients who were diagnosed with UCs or OCs on the basis of final pathology reports and who underwent surgery between January 1993 and January 2015 were included in the study. Data of patients were obtained from Gynecological Oncology Clinic electronic database and patient files...
July 2017: Journal of Obstetrics and Gynaecology Canada: JOGC, Journal D'obstétrique et Gynécologie du Canada: JOGC
https://www.readbyqxmd.com/read/28620240/mir-200c-driven-mesenchymal-to-epithelial-transition-is-a-therapeutic-target-in-uterine-carcinosarcomas
#4
Jill H Tseng, Maria Bisogna, Lien N Hoang, Narciso Olvera, Cristian Rodriguez-Aguayo, Gabriel Lopez-Berestein, Anil K Sood, Douglas A Levine, Petar Jelinic
Uterine carcinosarcomas (UCSs) are highly aggressive malignancies associated with poor prognoses and limited treatment options. These tumors are hypothesized to develop from the endometrial adenocarcinoma (EAC) through epithelial-mesenchymal transition (EMT). We test this long-standing hypothesis by depleting miR-200, a family of microRNAs critical for EMT, in EAC cell lines. Our data suggest that UCSs do not develop from EACs via EMT. Clinically more relevant, we show that miR-200 expression in UCS cells induces a robust mesenchymal-epithelial transition (MET)...
June 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28588782/rapidly-progressing-large-cell-neuroendocrine-carcinoma-arising-from-the-uterine-corpus-a-case-report-and-review-of-the-literature
#5
Aya Kobayashi, Tamaki Yahata, Sakiko Nanjo, Mika Mizoguchi, Madoka Yamamoto, Yasushi Mabuchi, Shigetaka Yagi, Sawako Minami, Kazuhiko Ino
Large-cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine tumor. LCNECs arising from the genital organs are highly malignant and rare, with <20 cases of LCNEC developing from the uterine endometrium reported to date. We herein present the case of a patient with LCNEC of the endometrium. The patient was a 52-year-old woman, who exhibited lower abdominal pain and rapid uterine enlargement during outpatient treatment for uterine myoma. The endometrial biopsy suggested a diagnosis of poorly differentiated carcinoma or carcinosarcoma...
June 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28584958/a-predictive-diagnostic-model-using-multiparametric-mri-for-differentiating-uterine-carcinosarcoma-from-carcinoma-of-the-uterine-corpus
#6
Yuki Kamishima, Mitsuru Takeuchi, Tatsuya Kawai, Takatsune Kawaguchi, Ken Yamaguchi, Naoki Takahashi, Masato Ito, Toshinao Arakawa, Akiko Yamamoto, Kazushi Suzuki, Masaki Ogawa, Moe Takeuchi, Yuta Shibamoto
PURPOSE: To construct a diagnostic model for differentiating carcinosarcoma from carcinoma of the uterus. MATERIALS AND METHODS: Twenty-six patients with carcinosarcomas and 26 with uterine corpus carcinomas constituted a derivation cohort. The following nine MRI features of the tumors were evaluated: inhomogeneity, predominant signal intensity, presence of hyper- and hypointense areas, conspicuity of tumor margin, cervical canal extension on T2WI, presence of hyperintense areas on T1WI, contrast defect area volume percentage, and degree of enhancement...
June 5, 2017: Japanese Journal of Radiology
https://www.readbyqxmd.com/read/28577885/isolated-tumor-cells-identified-by-sentinel-lymph-node-mapping-in-endometrial-cancer-does-adjuvant-treatment-matter
#7
Marie Plante, Jonathan Stanleigh, Marie-Claude Renaud, Alexandra Sebastianelli, Katherine Grondin, Jean Grégoire
OBJECTIVE: To evaluate the outcome and the role of adjuvant treatment in the management of patients with endometrial cancer and isolated tumor cells (ITCs) identified by SLN mapping. METHODS: This single center study identified all patients undergoing hysterectomy, salpingo-oophorectomy, lymphadenectomy and SLN mapping for endometrial cancer between November 2010 and December 2015. Data was prospectively collected. Progression-free survival was analyzed according to the Kaplan-Meier method and compared using the log-rank test...
May 31, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28574930/use-of-adjuvant-chemotherapy-radiation-therapy-or-combined-modality-therapy-and-the-impact-on-survival-for-uterine-carcinosarcoma-limited-to-the-pelvis
#8
Andrew T Wong, Yi-Chun Lee, David Schwartz, Anna Lee, Meng Shao, Peter Han, Kwang Choi, David Schreiber
OBJECTIVE: Clinical outcomes for patients with uterine carcinosarcoma are poor after surgical management alone. Adjuvant therapies including chemotherapy (CT) and/or radiation therapy (RT) have been previously investigated, but the optimal management of this disease remains controversial. The purposes of this study were to analyze the patterns of use of adjuvant CT and RT and to assess the impact on survival of each of these treatment regimens using the National Cancer Data Base. METHODS/MATERIALS: The National Cancer Data Base was queried for patients given a diagnosis of uterine carcinosarcoma confined to the pelvis who underwent total hysterectomy/bilateral salpingo-oophorectomy between 2004 and 2011...
June 1, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28546804/synchronous-uterine-adenocarcinoma-and-leiomyosarcoma-a-case-study
#9
Kamila Dudzik, Agnieszka Krzysteczko, Leon Kolny, Agnieszka Bąk, Ewelina Stawicka-Ociepka, Krzysztof Nowosielski
Synchronous gynecological cancers are rarely described. Those cases account for approximately up to 6% of female genital tract malignancies. The presence of synchronous endometrial adenocarcinoma and gynecological tract neoplasia is rare - the most commonly described is synchronous adenocarcinoma and endometrial ovarian cancer (accounting for 15-20% of ovarian neoplasia and 5% of endometrial cancers). Concomitant uterine carcinosarcoma and ovarian cancer, or endometrial adenocarcinoma are extremely rare. Up till now, only 3 cases of synchronous adenocarcinoma and leiomyosarcoma were described...
March 2017: Przeglad Menopauzalny, Menopause Review
https://www.readbyqxmd.com/read/28541634/prognostic-value-of-metabolic-parameters-determined-by-preoperative-%C3%A2-%C3%A2-f-fdg-pet-ct-in-patients-with-uterine-carcinosarcoma
#10
Hyun Ju Lee, Jong Jin Lee, Jeong Yeol Park, Jong Hyeok Kim, Yong Man Kim, Young Tak Kim, Joo Hyun Nam
OBJECTIVE: To evaluate the prognostic value of metabolic parameters measured by preoperative ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET)/computed tomography (CT) in patients with uterine carcinosarcoma (UCS). METHODS: Data of 55 eligible patients with UCS who underwent preoperative ¹⁸F-FDG PET/CT and surgical staging were analyzed retrospectively. Maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV₂.₅), and total lesion glycolysis (TLG₂...
July 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28531111/target-therapies-for-uterine-carcinosarcomas-current-evidence-and-future-perspectives
#11
REVIEW
Salvatore Giovanni Vitale, Antonio Simone Laganà, Stella Capriglione, Roberto Angioli, Valentina Lucia La Rosa, Salvatore Lopez, Gaetano Valenti, Fabrizio Sapia, Giuseppe Sarpietro, Salvatore Butticè, Carmelo Tuscano, Daniele Fanale, Alessandro Tropea, Diego Rossetti
Carcinosarcomas (CS) in gynecology are very infrequent and represent only 2-5% of uterine cancers. Despite surgical cytoreduction and subsequent chemotherapy being the primary treatment for uterine CS, the overall five-year survival rate is 30 ± 9% and recurrence is extremely common (50-80%). Due to the poor prognosis of CS, new strategies have been developed in the last few decades, targeting known dysfunctional molecular pathways for immunotherapy. In this paper, we aimed to gather the available evidence on the latest therapies for the treatment of CS...
May 20, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28498262/sarcoma-risk-in-uterine-surgery-in-a-tertiary-university-hospital-in-germany
#12
Sudip Kundu, Manuel Zachen, Hermann Hertel, Peter Hillemanns, Philipp Soergel
OBJECTIVES: There is a risk to incidentally spread uterine malignancies, especially sarcoma, if tissue is morcellated during hysterectomy or myoma enucleation. In the last years, a worldwide discussion has been started about this problem. However, the risk seems to be very small in recent studies. This study aims at further investigating the risk of disseminating uterine malignancy during uterine surgery in a tertiary university hospital in Germany. METHODS: In a retrospective setting, all cases of uterine myometrial surgery (hysterectomies and myomectomies) in our clinic during a period of 10 years were identified using clinical databases...
June 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28498249/clinicopathological-characteristics-and-prognostic-factors-of-synchronous-endometrial-and-ovarian-cancers-a-single-institute-review-of-43-cases
#13
Vandana Jain, Rupinder Sekhon, Sunil Pasricha, Shveta Giri, Kanika Batra Modi, Eliza Shrestha, Dharma Ram, Sudhir Rawal
OBJECTIVES: The objectives of our study were to demonstrate the clinicopathological characteristics and determine the prognostic factors for women with synchronous primary cancers of the endometrium and ovary. METHODS: A retrospective analysis of 43 pathologically proven cases of synchronous primary endometrial and ovarian cancers diagnosed between January 2005 and December 2015 was carried out. Patients with uterine sarcomas, carcinosarcomas, borderline tumors, and nonepithelial tumors of the ovary and patients who received neoadjuvant chemotherapy were excluded from the study...
June 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28469317/impact-of-surepath-%C3%A2-liquid-based-preparation-in-cytological-analysis-of-peritoneal-washing-in-practice-of-gynecologic-oncology
#14
Ruchita Tyagi, Nalini Gupta, Priyanka Bhagat, Shalini Gainder, Bhavna Rai, L K Dhaliwal, Arvind Rajwanshi
CONTEXT: Peritoneal washing is performed for staging of gynecologic tumors to detect subclinical intraperitoneal metastases. AIM: The aim of the present study was to assess the impact of SurePath™ liquid-based cytology (LBC) in peritoneal washing in various gynecological malignancies. SETTINGS AND DESIGN: An audit of peritoneal-fluid/washing (January 2012 to July 2013) was performed with corresponding gynecologic specimens. All peritoneal washings were processed using both conventional and LBC technique...
April 2017: Journal of Cytology
https://www.readbyqxmd.com/read/28464838/primary-extragenital-endometrial-stromal-sarcoma-of-the-lung-first-reported-case-and-review-of-literature
#15
Lara Alessandrini, Francesco Sopracordevole, Giulio Bertola, Simona Scalone, Martina Urbani, Gianmaria Miolo, Tiziana Perin, Fabrizio Italia, Vincenzo Canzonieri
BACKGROUND: Endometrial stromal sarcomas arising in extrauterine and extraovarian sites, in the absence of a primary uterine lesion are quite rare, especially in the absence of endometriosis. They usually present as an abdominal or pelvic mass lesion. CASE PRESENTATION: In 2007, a 45-year-old woman underwent total hysterectomy for in situ squamous cell carcinoma of the cervix. In 2014, an upper left pulmonary lobectomy was performed for a mass, which was provisionally diagnosed as primary carcinosarcoma of the lung...
May 2, 2017: Diagnostic Pathology
https://www.readbyqxmd.com/read/28457094/high-incidence-of-carcinosarcoma-among-patients-previously-treated-with-tamoxifen
#16
Yakir Segev, Ella Arnon, Efraim Siegler, Ofer Gemer, Yael Goldberg, Ron Auslender, Anis Kaldawy, Ofer Lavie
BACKGROUND: Tamoxifen acts as an estrogen antagonist within the breast tissue. In the uterus, tamoxifen is an agonist for some estrogen receptors and therefore can cause hyperplasia or neoplasia in the endometrium. OBJECTIVES: To compare characteristics of patients with uterine sarcoma who were and were not previously treated with tamoxifen. METHODS: The medical records of all women with uterine sarcoma who had been treated at the Carmel Medical Center in Haifa, Israel, during 2000-2013 were retrospectively reviewed...
March 2017: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/28424084/durable-complete-remission-with-aromatase-inhibitor-therapy-in-a-patient-with-metastatic-uterine-carcinosarcoma-with-poor-performance-status-and-coagulation-disorders-a-case-report
#17
P Martin-Romano, M Jurado, M A Idoate, L Arbea, J L Hernandez-Lizoain, D Cano, J A Paramo, S Martin-Algarra
BACKGROUND: Chemotherapy is considered the most appropriate treatment for metastatic uterine sarcoma, despite its limited efficacy. No other treatment has been conclusively proved to be a real alternative, but some reports suggest that anti-hormonal therapy could be active in a small subset of patients. We report the case of a patient with metastatic uterine carcinosarcoma with positive hormonal receptors and a complete pathological response. CASE PRESENTATION: A 54-year-old white woman presented to our emergency room with hypovolemic shock and serious vaginal bleeding...
April 19, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28392124/surgical-pathological-findings-in-type-1-and-2-endometrial-cancer-an-nrg-oncology-gynecologic-oncology-group-study-on-gog-210-protocol
#18
William T Creasman, Shamshad Ali, David G Mutch, Richard J Zaino, Matthew A Powell, Robert S Mannel, Floor J Backes, Paul A DiSilvestro, Peter A Argenta, Michael L Pearl, Shashikant B Lele, Saketh R Guntupalli, Steven Waggoner, Nick Spirtos, John F Boggess, Robert P Edwards, Virginia L Filiaci, David S Miller
OBJECTIVE: To report clinical and pathologic relationships with disease spread in endometrial cancer patients. METHODS: Surgical candidates with uterine cancer (adenocarcinoma or carcinosarcoma) who were eligible to participate in a surgical pathological study to create a clinically annotated tissue biorepository to support translational and clinical research studies. All patients were to undergo a hysterectomy, bilateral salpingo-oophorectomy, and bilateral pelvic and para-aortic lymphadenectomy...
June 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28319572/sarcomatous-component-in-uterine-carcinosarcomas-correlates-with-advanced-stage-and-poorer-prognosis
#19
Mirna B Podoll, Mana Moghadamfalahi, Erin Faber, Julie Ann Bishop, Houda Alatassi
Uterine carcinosarcomas, also known as malignant-mixed mullerian tumors, are rare and highly aggressive tumors whose prognostic factors remain controversial. The stage at the time of presentation is the most important prognostic factor thus far, but little information exists on the prognostic impact of the sarcomatous component (SC) in these tumors. We reviewed 21 cases of uterine carcinosarcomas and estimated the volume of the SC in each case. This information was correlated with the stage of the tumor at presentation...
March 17, 2017: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/28318642/stage-i-uterine-carcinosarcoma-matched-cohort-analyses-for-lymphadenectomy-chemotherapy-and-brachytherapy
#20
Brandon-Luke L Seagle, Margaux Kanis, Masha Kocherginsky, Jonathan B Strauss, Shohreh Shahabi
OBJECTIVE: To determine if lymphadenectomy, chemotherapy and radiotherapy are associated with survival benefit among women with stage I uterine carcinosarcoma. METHODS: Women with stage I uterine carcinosarcoma (n=5614) were identified from the 1998-2013 National Cancer Data Base. Kaplan-Meier survival estimates and Cox proportional-hazards regression models were used to evaluate predictors of overall survival. Effects of these predictors were also estimated using propensity score matched analyses for lymphadenectomy, adjuvant chemotherapy, and radiotherapy...
January 12, 2017: Gynecologic Oncology
keyword
keyword
46612
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"